Actively Recruiting
Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years
Led by GlaxoSmithKline · Updated on 2026-04-16
120
Participants Needed
2
Research Sites
41 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate the safety and immune response of a new formulation of pneumococcal vaccine, PnMAPS30plus, in healthy adults aged 50 to 64 years. Participants will receive a single dose of either the investigational vaccine or an approved pneumococcal vaccine (PCV20) and will be monitored for approximately six months. The study aims to determine if PnMAPS30plus is safe and well-tolerated and whether it helps the body produce antibodies that protect against pneumococcal disease.
CONDITIONS
Official Title
Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants able to comply with study requirements like completing electronic diaries and attending follow-up visits
- Provided written or witnessed informed consent before any study procedures
- Healthy or medically stable adults as confirmed by medical history and clinical exam
- Male and female adults aged 50 to 64 years at consent
- Female participants of childbearing potential must use adequate contraception and have a negative pregnancy test before vaccination
You will not qualify if you...
- History of invasive pneumococcal disease caused by S. pneumoniae within 3 years before vaccination
- History of allergic reactions or hypersensitivity to any vaccine components
- Confirmed or suspected immunosuppressive or immunodeficient conditions
- Allergy to latex
- Conditions preventing safe intramuscular vaccination or blood collection
- Documented HIV-positive status
- Acute or unstable chronic significant pulmonary, cardiovascular, liver, kidney, or metabolic conditions
- Recurrent uncontrolled neurological or neuroinflammatory disorders
- Behavioral, cognitive, or psychiatric disorders interfering with trial participation
- Any other clinical condition posing additional risk
- Use of investigational or non-registered products within 30 days before vaccination
- Previous pneumococcal vaccination
- Receipt or planned receipt of immunoglobulins or blood products within 90 days before or 30 days after vaccination
- Chronic or planned use of immune-modifying drugs lasting more than 14 consecutive days
- Pregnancy or lactation
- History or current chronic alcohol or drug abuse as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
GSK Investigational Site
Norwood, South Australia, Australia, 5067
Actively Recruiting
2
GSK Investigational Site
Camberwell, Victoria, Australia, 3124
Actively Recruiting
Research Team
U
US GSK Clinical Trials Call Center
CONTACT
E
EU GSK Clinical Trials Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here